Subject(s)
Adenocarcinoma/complications , Duodenum/pathology , Hematemesis/etiology , Pancreatic Neoplasms/complications , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Duodenum/diagnostic imaging , Endoscopy, Digestive System , Female , Hematemesis/diagnosis , Hematemesis/drug therapy , Humans , Middle Aged , Neoplasm Invasiveness , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Pantoprazole/administration & dosage , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: A new formulation of doxorubicin (pegylated liposomal doxorubicin) has been developed to attenuate the systemic side effects produced by this agent. Although pegylated liposomal doxorubicin has a much lower risk for cardiotoxicity, it has been associated with cutaneous side effects that differ from, and may also be more frequent than, those produced by the free form of the drug. METHODS: We report a case of interface dermatitis with keratinocyte dysmaturation, limited to the intertriginous areas, in a patient who received pegylated liposomal doxorubicin, and we review the literature. RESULTS: It is possible that the enhanced delivery of doxorubicin in liposomal form promotes cutaneous side effects of the drug. We consider the possible mechanisms for keratinocyte dysmaturation produced by this form of doxorubicin. CONCLUSIONS: Our findings further suggest that inflammatory changes seen on biopsy may not always allow a reliable histopathologic distinction between this chemotherapy effect and graft-versus-host disease.
